Terminal · Institutions
Every 13F-reported equity position this quarter, with its quarter-over-quarter change — each row traces back to the SEC filing.
Every 13F-reported equity position this quarter, with its quarter-over-quarter change — each row traces back to the SEC filing.
Kalehua Capital Management LLC (CIK 2106181) reported $174.0M across 26 reported positions in its SEC 13F filing for 2026-06-30. Largest positions: BOXX ($26.5M, 15.22%), MANE ($17.9M, 10.30%), XFOR ($17.4M, 9.99%), CMPS ($11.6M, 6.67%), SRZN ($10.0M, 5.75%). Source: SEC Form 13F.
| Rank | Ticker | Company | Value | % Portfolio | Shares | Action |
|---|---|---|---|---|---|---|
| 1 | BOXX | EA SERIES TRUST | $26.5M | 15.22% | 226,188 | Trimmed |
| 2 | MANE | Veradermics Inc | $17.9M | 10.30% | 145,695 | Trimmed |
| 3 | XFOR | X4 Pharmaceuticals Inc | $17.4M | 9.99% | 3.7M | Hold |
| 4 | CMPS | Compass Pathways Plc | $11.6M | 6.67% | 819,692 | Hold |
| 5 | SRZN | Surrozen Inc | $10.0M | 5.75% | 385,178 | Hold |
| 6 | ACRS | Aclaris Therapeutics Inc | $9.7M | 5.57% | 1.8M | Trimmed |
| 7 | SION | Sionna Therapeutics Inc | $8.7M | 4.98% | 197,072 | Hold |
| 8 | IKT | Inhibikase Therapeutics Inc | $7.8M | 4.46% | 3.8M | Trimmed |
| 9 | PHVS | Pharvaris NV | $6.9M | 3.95% | 198,772 | Hold |
| 10 | KPTI | Karyopharm Therapeutics Inc | $6.7M | 3.85% | 685,644 | New |
| 11 | SEPN | Septerna Inc | $6.5M | 3.75% | 194,544 | Hold |
| 12 | IFRX | Inflarx Nv | $6.5M | 3.73% | 2.9M | New |
| 13 | CYCN | Cyclerion Therapeutics Inc | $5.6M | 3.22% | 1.7M | New |
| 14 | KRRO | Korro Bio Inc | $5.3M | 3.07% | 405,040 | Added |
| 15 | QURE | Uniqure Nv | $3.7M | 2.10% | 79,407 | Trimmed |
| 16 | LONA | LeonaBio Inc | $3.6M | 2.08% | 393,701 | Hold |
| 17 | DMRA | Damora Therapeutics Inc | $3.6M | 2.08% | 139,000 | Hold |
| 18 | MLTX | MoonLake Immunotherapeutics | $3.4M | 1.97% | 175,734 | Hold |
| 19 | ANL | Adlai Nortye | $2.6M | 1.50% | 226,415 | New |
| 20 | TYRA | Tyra Biosciences Inc | $2.4M | 1.37% | 74,465 | Hold |
| 21 | NVCT | Nuvectis Pharma Inc | $1.8M | 1.06% | 100,000 | New |
| 22 | GOSS | Gossamer Bio Inc | $1.8M | 1.05% | 11.1M | Trimmed |
| 23 | MIST | Milestone Pharmaceuticals Inc | $1.7M | 0.98% | 1.3M | New |
| 24 | ATYR | Atyr Pharma Inc | $1.1M | 0.61% | 1.8M | New |
| 25 | TIL | Instil Bio Inc | $765,924 | 0.44% | 99,600 | Trimmed |
Source: SEC Form 13F filings · as of 2026-06-30